Skip to main content
Clinical Trials/ACTRN12615000460505
ACTRN12615000460505
Terminated
Phase 1

In people with treatment resistant schizophrenia, is sodium benzoate a tolerated and acceptable augmentation strategy: a phase Ib/II study.

niveristy of Otago0 sites1 target enrollmentMay 12, 2015

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
niveristy of Otago
Enrollment
1
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2015
End Date
June 1, 2016
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niveristy of Otago

Eligibility Criteria

Inclusion Criteria

  • 1\.A clinical diagnosis of Schizophrenia, confirmed by a structured diagnostic interview.
  • 2\.Have a body mass index between 18 and 35 (that is, not underweight or markedly overweight)
  • 3\.Have had no major change in their symptoms for three months.
  • 4\.Have moderate to severe current symptom

Exclusion Criteria

  • 1\.You are pregnant or are intending to become pregnant.
  • 2\.Have a history of alcohol or drug dependance.
  • 3\.Have a history of epilepsy, head injury, or a neurological disorder.
  • 4\.If participating in the trial would place you at unacceptable risk.
  • 5\.If you are considered highly likely to not take any medications, as part of the study or not.

Outcomes

Primary Outcomes

Not specified

Similar Trials